Biosimilars on the Brink

Biosimilars—follow-on products of innovator biopharmaceuticals—will transform the drug marketplace, according to Steve Grossman writing in Perspectives. This despite substantial skepticism.

Starting as early as 2014, FDA approval of biosimilars could begin to accelerate. Once price competition kicks in, industry economics will transform.

Although the FDA may not issue guidance for several months, recent publications and industry interactions suggest that key officials are already laying the groundwork for these products. Drugmakers, meanwhile, are considering new business models, and, in some cases, committing substantial investment dollars and defining a new product line.

Read "Biosimilars and Market Transformation" here.